Patient-Reported Outcomes with Insulin Glargine 300 U/mL in People with Type 2 Diabetes: The MAGE Multicenter Observational Study

INTRODUCTION: MAGE was a Multicenter, single-Arm, observational 6-month (plus 6-month extension) study that aimed to assess treatment satisfaction, efficacy, and safety of insulin Glargine 300 U/mL (Gla-300) in people with type 2 diabetes (T2DM) receiving basal-bolus insulin in a rEal-world setting....

Descripción completa

Detalles Bibliográficos
Autores principales: Colin, Ides M., Alexandre, Kathy, Bruhwyler, Jacques, Scheen, André, Verhaegen, Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376812/
https://www.ncbi.nlm.nih.gov/pubmed/32643130
http://dx.doi.org/10.1007/s13300-020-00866-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376812/
https://www.ncbi.nlm.nih.gov/pubmed/32643130
http://dx.doi.org/10.1007/s13300-020-00866-2

Ejemplares similares